Observational studyInternational journal of hematology2026
Clinical impact of a rapid multiplex PCR assay on the diagnosis and management of viral infections after HSCT.
Observational study in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Hematopoietic stem cell transplantation (HSCT) recipients are highly susceptible to viral infections, many of which are missed by conventional diagnostic tests owing to limited coverage and slow turnaround times. This single-center, prospective observational study evaluated a rapid multiplex PCR (mPCR) assay to detect 13 DNA viruses for diagnosis and management of post-HSCT viral infections. Between December 2020 and March 2025, 63 HSCT recipients with suspected viral infections underwent mPCR testing of blood (n = 51) or cerebrospinal fluid (CSF) (n = 12) in parallel with standard diagnostics. The mPCR results were reported within 24 h and integrated into clinical decision-making. The etiology was identified in 44 of 51 (86%) blood samples (30 infections) and 9 of 12 (75%) CSF samples (5 infections). mPCR provided the sole etiological diagnosis in 19 of 63 (30%) episodes: 15 of 51 (29%) blood and 4 of 12 (33%) CSF samples. mPCR enabled targeted treatment in 15 of 63 (24%) episodes: 11 of 51 (22%) blood and 4 of 12 (33%) CSF samples. Unexpected infections, such as varicella-zoster virus meningitis and human herpesvirus 7 encephalitis, were identified only by mPCR. Rapid mPCR provided timely, actionable diagnosis and directly influenced the clinical management of post-HSCT patients.
Indexed as
Identifiers
41214386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.